<DOC>
	<DOCNO>NCT00304499</DOCNO>
	<brief_summary>The purpose study compare side-effect profile efficacy sustain release , OROS® TTS , dosage form oxybutynin immediate release ( IR ) oral oxybutynin placebo .</brief_summary>
	<brief_title>Efficacy Safety OROS Oybutynin TTS Oxybutynin Middle-Aged Elderly Women With Urinary Incontinence</brief_title>
	<detailed_description>Urinary incontinence ( UI ) refers involuntary loss urine sufficient amount consider social health problem . While psychologically distress socially disruptive , UI believe report diagnosed medical condition . This Multicenter , randomize , double-blind , placebo-controlled , parallel group study 1 week single-blinded placebo run-in . Patients randomize 6 week double-blind treatment oxybutynin placebo . The primary hypothesis test study treatment difference change incontinence episode per week 6 week treatment double-blind phase individual oxybutynin-treated group combine placebo group equal zero . The patient receive oral OROS® contain oxybutynin , immediate release oral oxybutynin ( 1.7 2.5 mg ) TTS oxybutynin ( 60 cm2 ) daily 7 week .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Women , age 40 year old , screen PUD demonstrate average urinary frequency 10 per 24 hour urge incontinence episodes ³10 time per week £ 60 time per week , CMG demonstrate detrusor contraction and/or severe `` must void '' urge ( score = 2 ) bladder fill volume less equal 400 mL Women mix incontinence provide symptom and/or sign stress incontinence predominant manifestation UI urge incontinence episode associated urgency differentiate urge incontinence episode associated urgency Patients mentally intact capable understand follow study requirement Each patient must determine good general health prior study participation . The evaluation base medical history Physical examination ( general , genital , pelvic , rectal ) Laboratory test include blood chemistry profile ( glucose , blood urea nitrogen , uric acid , calcium , phosphorus , total protein , albumin , cholesterol , total bilirubin , alkaline phosphatase , aspartate aminotransferase , alanine aminotransferase , lactate dehydrogenase , sodium , potassium , creatinine , bicarbonate chloride ) Complete blood count ( CBC ) differential platelet Urinalysis microscopic examination And electrocardiogram ( EKG ) Creatinine clearance ( Ccr ) estimate 0.85 x ( 140Age ) x ( body weight Kg ) ¸ ( 72 x serum creatinine mg/dl ) . The estimated Ccr must great 50 mL/min Normotensive supine blood pressure range 100 140 mm Hg systolic 6590 mm Hg diastolic , clinically significant postural hypotension 30 second 2 minute stand . If patient take antihypertensive medication ( may include calcium channel blocker undissolvable dosage form ) , must normotensive antihypertensive medication . Patients stable dose antihypertensive medication least 90 day screen study plan change dose antihypertensive medication study Premenopausal woman must use medically acceptable effective birth control method ( birth control pills implant , IUD , diaphragm spermicide , condom spermicide spermicidecontaining sponge ) negative urine pregnancy test time screen Patients positive urine culture screen may treat antibiotic urine culture negative follow treatment patient antibiotic period one week patient may rescreened . The patient 's urine culture negative patient begin record screen urinary diary CMG Patients known genitourinary condition ( identify history examination ) may cause incontinence ( eg , urinary tract infection , obstruction , bladder tumor , bladder stone ) Patients clinically significant medical problem organ abnormality pathology , opinion investigator , administration oxybutynin would present undue risk ( cardiovascular , pulmonary , gastrointestinal , renal , endocrine , neurological , rheumatological , hematological , urologic , psychiatric disorder include depression ) Patients glaucoma untreated narrow anterior chamber angle ( determined examination history ) , obstructive disease severe narrow gastrointestinal tract , obstructive uropathy , myasthenia gravis Patients receive drug consider effective treatment urinary incontinence include dicyclomine , imipramine , propantheline , hyoscyamine ( Levsin® ) , flavoxate , phenylpropanolamine , prazosin , pseudoephedrine , baclofen ( Lioresal® ) , terodiline less equivalent 5 time halflife drug Patients treat anticholinergic agent urge UI find refractory agent . ( Note : Patients show responder anticholinergic medication may include study appropriate washout period equivalent 5 time halflife anticholinergic drug ) Concomitant medication ( include overthecounter medication ) study exception medication take regularly chronic condition intermittently treatment mild pain , ( eg , acetaminophen , nonsteroidal antiinflammatory drug Estrogen replacement therapy , oral contraceptive , diuretic , calcium channel blocker ) Patients take investigational drug within period one month 5 time halflife drug ( whichever longer ) Hemoglobin le 10 g/dL Known allergy hypersensitivity oxybutynin Patients history drug alcohol abuse ( &gt; 2 drink day : 1 drink define 12oz beer , 1oz hard liquor 4oz wine ) Positive urine drug screen Pregnant lactating Patients , investigator 's opinion , may capable follow study schedule reason</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>OROS®</keyword>
	<keyword>middle age</keyword>
	<keyword>elderly</keyword>
	<keyword>oxybutynin</keyword>
	<keyword>urinary incontinenence</keyword>
	<keyword>woman</keyword>
</DOC>